Share on LinkedInShare on LinkedIn

ARTICLE · 21 MAY 2008

Still Room For Argument On Pharmaceutical Repackaging

In the recent decision of Boehringer Ingelheim KG v Swingward Limited, the Court of Appeal has considered and applied the ECJ decision of April 2007 after a second reference from the English Courts in the same proceedings on the issue of repackaged pharmaceutical parallel imports within the EEA.

United KingdomIntellectual Property
Lucy Harrold
Lucy Harrold

In the recent decision of Boehringer Ingelheim KG v Swingward Limited1, the Court of Appeal has considered and applied the ECJ decision of April 2007 after a second reference from the English Courts in the same proceedings on the issue of repackaged pharmaceutical parallel imports within the EEA. It holds in favour of the parallel importers but reserves its final judgment pending the outcome of a related Austrian reference to the ECJ.

BACKGROUND

This case concerns the circumstances in which a proprietor may rely on his trade mark rights to prevent a parallel importer from marketing products he has repackaged bearing the trade mark. The claimants are pharmaceutical companies and the defendants are parallel importers of pharmaceuticals manufactured and marketed within the EEA by the claimants. The case first came before the English High Court in January 2000 (see [2000] F.S.R. 529). In April 2002,

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

See more popular content from